Holmes Biopharma, Inc. (LMB) Reports Q2 EPS of $0.09, Revenues Beat; Lifts FY18 Revenue Outlook Above Consensus

Go back to Holmes Biopharma, Inc. (LMB) Reports Q2 EPS of $0.09, Revenues Beat; Lifts FY18 Revenue Outlook Above Consensus

Limbach Holdings Reports Second Quarter 2018 Results

August 14, 2018 4:15 PM EDT

Q2 2018 Revenues up 18.4% Versus Prior Year; Aggregate Backlog of $492.5 million at Quarter End

Conference Call Scheduled for 9:00am ET Wednesday August 15, 2018

PITTSBURGH--(BUSINESS WIRE)-- Limbach Holdings, Inc. (NASDAQ: LMB) (Limbach or the Company) today announced financial results for the quarter ended June 30, 2018. Total Q2 2018 revenues increased 18.4% versus the prior year period to $139.5 million. Construction segment revenue grew 18.2% from the prior year period while Service segment revenues gained 19.3%.

Other key financial highlights of the quarter included:

Gross margin was 11.3% in the second... More